please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vivo Bio Tech reported standalone revenue of Rs. 5,257 Lakhs for FY26, up 12.6% from Rs. 4,667 Lakhs in FY25. However, the company swung to a net loss of Rs. 194 Lakhs (standalone) and Rs. 171 Lakhs (consolidated) from a profit of Rs. 757 Lakhs in the previous year. The Q4 standalone loss was Rs. 544 Lakhs. Revenue grew but profitability turned negative due to higher employee costs, increased depreciation, and a prior period expense of Rs. 60 Lakhs. The auditor issued an unmodified opinion but included an Emphasis of Matter noting unpaid statutory dues of Rs. 420 Lakhs including PF, ESI, TDS, and self-assessment tax. The company also approved a material related party transaction and appointed an advisor for a proposed scheme of arrangement/amalgamation.
The company showed revenue growth but swung to losses, which is negative for shareholders. The unpaid statutory dues highlighted by the auditor raise compliance concerns. However, strong operating cash flow of Rs. 3,611 Lakhs and an unmodified audit opinion provide some comfort.